Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
G6PC3 promotes genome maintenance and is a candidate mammary tumor suppressor
Xin Li, … , Finn Cilius Nielsen, Claus Storgaard Sørensen
Xin Li, … , Finn Cilius Nielsen, Claus Storgaard Sørensen
Published April 22, 2025
Citation Information: JCI Insight. 2025;10(11):e186747. https://doi.org/10.1172/jci.insight.186747.
View: Text | PDF
Research Article Cell biology Clinical Research Genetics

G6PC3 promotes genome maintenance and is a candidate mammary tumor suppressor

  • Text
  • PDF
Abstract

Mutations in genome maintenance factors drive sporadic and hereditary breast cancers. Here, we searched for potential drivers based on germline DNA analysis from a cohort consisting of patients with early-onset breast cancer negative for BRCA1/BRCA2 mutations. This revealed candidate genes that subsequently were subjected to RNA interference–based (RNAi-based) phenotype screens to reveal genome integrity effects. We identified several genes with functional roles in genome maintenance, including Glucose-6-Phosphatase Catalytic Subunit 3 (G6PC3), SMC4, and CCDC108. Notably, G6PC3-deficient cells exhibited increased levels of γH2AX and micronuclei formation, along with defects in homologous recombination (HR) repair. Consistent with these observations, G6PC3 was required for the efficient recruitment of BRCA1 to sites of DNA double-strand breaks (DSBs). RNA-Seq analysis revealed that G6PC3 promotes the expression of multiple homologous recombination repair genes, including BRCA1. Through CRISPR-Select functional-genetic phenotype analysis of G6PC3 germline mutations, we identified 2 germline G6PC3 variants displaying partial loss of function. Furthermore, our study demonstrated that G6pc3 deficiency accelerates mammary tumor formation induced by Trp53 loss in mice. In conclusion, our cohort-based functional analysis has unveiled genome maintenance factors and identified G6PC3 as a potential candidate tumor suppressor in breast cancer.

Authors

Xin Li, Maria Rossing, Ana Moisés da Silva, Muthiah Bose, Thorkell Gudjónsson, Jan Benada, Jayashree Thatte, Jens Vilstrup Johansen, Judit Börcsök, Hanneke van der Gulden, Ji-Ying Song, Renée Menezes, Asma Tajik, Lucía Sena, Zoltan Szallasi, Morten Frödin, Jos Jonkers, Finn Cilius Nielsen, Claus Storgaard Sørensen

×

Figure 5

KO of potential genome maintenance factors accelerates mammary tumorigenesis in a Trp53-deficient somatic breast cancer mouse model.

Options: View larger image (or click on image) Download as PowerPoint
KO of potential genome maintenance factors accelerates mammary tumorigen...
(A) Schematic diagram of somatic mouse models of breast cancer, intraductally injected with high-titer lentiviruses encoding Cre and nontargeting (NT) sgRNA, or sgRNAs targeting Brca1, Ccdc108, or G6pc3 alleles in Rosa26-Cas9;Trp53fl/fl females. G6pc3 KO results in tumor formation. Tumors were harvested and undergo histopathology and TIDE analysis. (B) Kaplan-Meier analysis of mammary tumor-free survival of Rosa26-Cas9;Trp53fl/fl mice injected with sgNT (sgBrca1 vs sgNT: P = 0.271; sgCcdc108 vs sgNT: P = 0.620; sgG6pc3 vs sgNT: P = 0.190, Cox proportional hazards model). The different groups don’t show a significant difference in tumor onset. The number of animals at risk over time is represented in the bottom table. One animal in the Brca1 cohort and 1 in the Ccdc108 aren’t represented because they were euthanized due a tumor before 200 days after injection. (C) Kaplan-Meier analysis of overall survival of Rosa26-Cas9;Trp53fl/fl females injected with sgNT (n = 7), sgBrca1 (n = 7), sgCcdc108 (n = 12), and sgG6pc3 (n = 8). (sgBrca1 vs sgNT: P = 0.00250; sgCcdc108 vs sgNT: P = 0.02044; sgG6pc3 vs sgNT: P = 0.00431, Cox proportional hazards model). The number of animals at risk over time is represented in the bottom table. Two mice in the G6pc3 cohort aren’t represented because they were euthanized due a tumor before 200 days after injection. (D) Histopathological classification of the main tumor of each mouse injected with sgNT (n = 3), sgBrca1 (n = 7), sgCcdc108 (n = 10), or sgG6pc3 (n = 7). (E) H&E stained representative images of the 3 different tumor types present in the cohorts, sarcoma (sgG6pc3 tumor no. 2211174), carcinoma (sgBrca1 tumor no. 2218975), and mixed lesion (sgG6pc3 tumor no. 2312753). Scale bar, 200 μm.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts